Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
12/2003
12/10/2003CN1130355C Thienyl-, furyl-, pyrrolyl-and biphenylsulfonamides and derivatives thereof modulate activity of endothelin
12/10/2003CN1130347C 2,3-methylene amino acid compounds, their preparing method and pharmaceutical composition containing them
12/10/2003CN1130222C Aqueous prolonged release formulation
12/10/2003CN1130218C Chinese medicine preparation for treating spinal damage and its preparing method
12/10/2003CN1130214C Medicine for treating purpura caused by lupus erythematosus and other immunological disease
12/10/2003CN1130200C Glucocorticoid receptor antagonists for treatment of dementia
12/10/2003CA2389911A1 Broad spectruma antagonists and vaccines directed against pyrogenic exotoxins
12/09/2003US6660879 Use of the compound in clinical conditions associated with insulin resistance.
12/09/2003US6660859 Arylpiperzine derivatives are useful for treatment of anxiety, depression, hypertension, cognitive disorders, sexual dysfunction, brain trauma, memory loss, eating disorders, obesity, substance abuse, and obsessive-compulsive diseases
12/09/2003US6660843 Fusion of Fc domains with biologically active peptides
12/09/2003US6660830 Peptides with antiproliferative properties
12/09/2003US6660767 Coumarin compounds as microtubule stabilizing agents and therapeutic uses thereof
12/09/2003US6660763 Bis-indolylquinone compounds
12/09/2003US6660759 4.5-diaryloxazole compounds with prostaglandin I2 (PGI2) agonistic activity
12/09/2003US6660751 Sulfonamide derivatives as 5-HT7 receptor antagonists
12/09/2003US6660748 1-azabicyclo(2.2.1)heptane or quinuclidine derivatives; treating or preventing neuronal damage associated with neurological diseases
12/09/2003US6660746 Cardiovascular disorders
12/09/2003US6660745 Phosphodiesterase inhibitors; treatment of asthma, chronic obstructive pulmonary disease, inflammatory disorders
12/09/2003US6660744 Pyrazolopyrimidines as therapeutic agents
12/09/2003US6660740 Sorbitol dehydrogenase inhibitors
12/09/2003US6660738 Such as (3R,5S)-1-pyrimidin-2-yl-5-(2,4,5-trifluoro-benzyloxymethyl)-pyrrolidine-3 -thiol trifluoro-acetate useful as inhibitors of metalloproteases for treating diseases associated with vasoconstriction
12/09/2003US6660737 Medicinal uses of hydrazones
12/09/2003US6660736 MAO-B inhibitors
12/09/2003US6660732 Ureas and thioureas inhibit production of cytokines
12/09/2003US6660728 Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
12/09/2003US6660725 Method and composition for modulating amyloidosis
12/09/2003US6660722 Therapeutical treatments
12/09/2003US6660279 Stability for injection solutions
12/09/2003US6660268 Proteasome regulation of NF-KB activity
12/09/2003CA2266318C Flavonol containing food supplements
12/09/2003CA2264985C 6,8-dimercarptooctanoic acid derivatives substituted in 6-s and/or 8-s by the radical (3-methylthiopropanoyl) and pharmaceutical compositions used to treat cancerous tumors
12/09/2003CA2202075C Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using
12/09/2003CA2140247C Novel vitamin d analogues
12/09/2003CA2086811C 4,13-dioxabicyclo [8.2.1] tridecenone compounds process and intermediates for their preparation and pharmaceutical compositions containing them
12/09/2003CA2078758C 2-substituted indane-2-mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
12/04/2003WO2003100438A1 Assays for modulators of asparaginyl hydroxylase
12/04/2003WO2003100427A1 Method for identification of a ligand whereby receptor residence time is measured
12/04/2003WO2003100087A2 Regulation of novel human asparagine-hydroxylases
12/04/2003WO2003100064A1 Novel ubiquitin ligase
12/04/2003WO2003099839A1 Modulators and inhibitors of fibroblast growth factor receptor 5_polypeptides and gene expression thereof.
12/04/2003WO2003099827A1 1-thia-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
12/04/2003WO2003099823A2 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
12/04/2003WO2003099820A1 Pyrazolo-pyrimidine aniline compounds
12/04/2003WO2003099819A2 Oxophenyl-cyclohexyl-propanolamine derivatives, production and use thereof in therapeutics
12/04/2003WO2003099818A1 Substituted quinazolinone compounds
12/04/2003WO2003099814A1 Calcium receptor modulating agents
12/04/2003WO2003099813A1 Novel physiolgically active substances
12/04/2003WO2003099811A1 Kinase inhibitors
12/04/2003WO2003099809A1 HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY α4 INTEGRINS
12/04/2003WO2003099807A1 New indolylpiperidine derivatives as potent antihistaminic and antiallergic agents
12/04/2003WO2003099805A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
12/04/2003WO2003099796A1 Protein kinase inhibitors
12/04/2003WO2003099786A2 Aromatic sulfones and their medical use
12/04/2003WO2003099783A2 Tropane compounds
12/04/2003WO2003099775A1 Sulfone liver x-receptor modulators
12/04/2003WO2003099773A1 Ccr9 inhibitors and methods of use thereof
12/04/2003WO2003099772A1 Phenylcyclohexylpropanolamine derivatives, preparation and therapeutic application thereof
12/04/2003WO2003099771A2 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
12/04/2003WO2003099767A1 Amide derivatives as inhibitors of the enzymatic activity of renin
12/04/2003WO2003099766A1 (2s)-2-ethylphenylpropionic acid derivative
12/04/2003WO2003099765A1 β-ALANINE DERIVATIVE AND USE THEREOF
12/04/2003WO2003099764A1 ALKOXY ARYL β2 ADRENERGIC RECEPTOR AGONISTS
12/04/2003WO2003099763A1 N-acylaminobenzene dervatives as selective monoamine oxidase b inhibitors
12/04/2003WO2003099752A1 Gingerol analogues and use thereof
12/04/2003WO2003099337A2 Inclusion complexes of rosiglitazone
12/04/2003WO2003099334A1 Topically applicable pharmaceutical preparation
12/04/2003WO2003099332A1 Medicinal composition for inhibiting the expression of atp-citrate lyase and use thereof
12/04/2003WO2003099331A1 Insulin resistance improving agents
12/04/2003WO2003099327A1 Parakeratosis inhibitor, pore-shrinking agent and skin preparation for external use
12/04/2003WO2003099323A1 Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
12/04/2003WO2003099319A1 Preventive/remedy for arteriosclerosis
12/04/2003WO2003099316A1 Heterocyclicsulfonamide hepatitis c virus inhibitors
12/04/2003WO2003099309A1 Active fraction having anti-cancer and anti-metastasis isolated from acanthopanax species and fruits
12/04/2003WO2003099308A1 Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng
12/04/2003WO2003099294A1 Drugs improved in tissue selectivity
12/04/2003WO2003099288A1 Medicinal composition
12/04/2003WO2003099281A2 Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
12/04/2003WO2003099280A1 Novel formulation for the parenteral application of crobenetine
12/04/2003WO2003099278A1 Ophthalmological use of roflumilast for the treatment of diseases of the eye
12/04/2003WO2003099275A1 Method for the use of pyranoindole derivatives to treat infection with hepatitis c virus
12/04/2003WO2003099274A1 Hepatitis c virus inhibitors
12/04/2003WO2003099270A1 Methods of treating allergic reactions
12/04/2003WO2003099231A2 Heteroaryl compounds which inhibit leukocyte adhesion mediated by alpha-4 integrins
12/04/2003WO2003099221A2 Methods for using jnk inhibitors for treating or preventing disease-related wasting
12/04/2003WO2003099218A2 Anti-cancer formulation
12/04/2003WO2003099201A2 Compositions and methods of use for a fibroblast growth factor
12/04/2003WO2003099194A2 Pharmaceutical combination of pde5 inhibitors with ace inhibitors
12/04/2003WO2003099037A1 Probiotics and oral tolerance
12/04/2003WO2003099011A1 Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
12/04/2003WO2003098992A2 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
12/04/2003WO2003086309A3 NF-κB INHIBITORS
12/04/2003WO2003080841A8 Calcineurin activators
12/04/2003WO2003075928A3 Stable pharmaceutical compositions
12/04/2003WO2003075921A3 Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
12/04/2003WO2003074485A3 Indole-amide derivatives and their use as glycogen phosphorylase inhibitors
12/04/2003WO2003070728A3 Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders
12/04/2003WO2003068790A3 Macrolide antibacterial compounds
12/04/2003WO2003066604A3 Novel aryl- and heteroarylpiperazines
12/04/2003WO2003063794A3 2,4-pyrimidinediamine compounds and their uses
12/04/2003WO2003062200A3 Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists
1 ... 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 ... 1564